[Allogeneic transplantation as a therapeutic option for atypical chronic myeloid leukemia].
Rinsho Ketsueki
; 65(9): 967-975, 2024.
Article
em Ja
| MEDLINE
| ID: mdl-39358297
ABSTRACT
Atypical chronic myeloid leukemia (aCML) is a rare disease classified as a myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Recent advances in gene mutational profiling have clarified the characteristics of aCML as a disease entity relative to other MDS/MPNs. Although some studies suggest the efficacy of DNA demethylating agents and tyrosine kinase inhibitors, data about these agents are limited due to the small number of patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is only therapeutic option that can provide durable remission for aCML and other MDS/MPNs. Retrospective studies from Europe and Japan revealed the clinical results of allo-HSCT for aCML. This review summarizes the pathogenesis of aCML and the development of allo-HSCT and other therapeutic options.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante Homólogo
/
Transplante de Células-Tronco Hematopoéticas
Limite:
Humans
Idioma:
Ja
Revista:
Rinsho Ketsueki
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Japão